Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
UTAA09/17-gammadeltaT by PersonGen BioTherapeutics (Suzhou) for Follicular Lymphoma: Likelihood of Approval
UTAA09/17-gammadeltaT is under clinical development by PersonGen BioTherapeutics (Suzhou) and currently in Phase I for Follicular Lymphoma. According to GlobalData,...
Data Insights
UTAA09/17-gammadeltaT by PersonGen BioTherapeutics (Suzhou) for Mantle Cell Lymphoma: Likelihood of Approval
UTAA09/17-gammadeltaT is under clinical development by PersonGen BioTherapeutics (Suzhou) and currently in Phase I for Mantle Cell Lymphoma. According to...